Enovis Co. (NYSE:ENOV) is Cove Street Capital LLC’s 10th Largest Position

Cove Street Capital LLC lifted its holdings in Enovis Co. (NYSE:ENOV – Get Rating) by 0.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 210,171 shares of the company’s stock after purchasing an additional 1,784 shares during the period. Enovis comprises 3.1% of Cove Street Capital LLC’s holdings, making the stock its 10th biggest position. Cove Street Capital LLC’s holdings in Enovis were worth $11,248,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Bank of America Corp DE grew its position in Enovis by 35.6% during the fourth quarter. Bank of America Corp DE now owns 303,789 shares of the company’s stock valued at $16,259,000 after buying an additional 79,771 shares during the period. Amalgamated Bank increased its position in shares of Enovis by 23.6% during the fourth quarter. Amalgamated Bank now owns 42,780 shares of the company’s stock valued at $2,290,000 after acquiring an additional 8,169 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Enovis by 16.0% during the fourth quarter. Schroder Investment Management Group now owns 89,904 shares of the company’s stock valued at $4,812,000 after acquiring an additional 12,406 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enovis during the fourth quarter valued at about $1,364,000. Finally, Victory Capital Management Inc. increased its position in shares of Enovis by 4.1% during the fourth quarter. Victory Capital Management Inc. now owns 433,296 shares of the company’s stock valued at $23,190,000 after acquiring an additional 16,954 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Insider Buying and Selling

In other Enovis news, CEO Matthew L. Trerotola sold 18,917 shares of the business’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $56.21, for a total value of $1,063,324.57. Following the sale, the chief executive officer now directly owns 175,910 shares in the company, valued at $9,887,901.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Enovis news, CEO Matthew L. Trerotola sold 6,743 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $57.69, for a total transaction of $389,003.67. Following the sale, the chief executive officer now owns 197,388 shares in the company, valued at approximately $11,387,313.72. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Matthew L. Trerotola sold 18,917 shares of the business’s stock in a transaction dated Monday, February 27th. The stock was sold at an average price of $56.21, for a total value of $1,063,324.57. Following the sale, the chief executive officer now owns 175,910 shares in the company, valued at approximately $9,887,901.10. The disclosure for this sale can be found here. Insiders sold 51,557 shares of company stock valued at $2,900,121 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ENOV shares. Robert W. Baird lifted their price objective on shares of Enovis from $64.00 to $67.00 in a report on Friday, May 5th. Wells Fargo & Company upgraded shares of Enovis from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $55.00 to $67.00 in a research report on Friday, May 12th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Tuesday, March 28th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $64.88.

Enovis Trading Up 0.5 %

ENOV traded up $0.27 on Friday, reaching $52.97. 200,086 shares of the company’s stock were exchanged, compared to its average volume of 418,358. The company’s 50 day moving average is $54.85 and its 200-day moving average is $56.34. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $68.15. The company has a quick ratio of 1.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.08.

Enovis (NYSE:ENOV – Get Rating) last announced its quarterly earnings data on Thursday, May 4th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Enovis had a positive return on equity of 3.70% and a negative net margin of 3.24%. The firm had revenue of $406.20 million for the quarter, compared to analysts’ expectations of $389.95 million. During the same period last year, the business posted $0.37 earnings per share. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, sell-side analysts forecast that Enovis Co. will post 2.27 earnings per share for the current year.

Enovis Profile

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.